Skip to main content

Biodesix Inc

corporate_fare Company Profile

Biodesix Inc

BDSX·NASDAQ·Industrial Applications And Services·CIK 0001439725

Biodesix, Inc. is a diagnostic solutions company that aims to transform patient care and improve outcomes through personalized diagnostics. The company generates revenue from two primary sources: Biodesix Lung Diagnostic Testing and Biodesix Development Services. Lung Diagnostic Testing provides blood-based diagnostic testing services for healthcare providers, utilizing five proprietary tests. Development Services offers diagnostic testing and consulting to biopharmaceutical, life sciences, and diagnostic companies. In 2025, Biodesix achieved an estimated total revenue of $88.5 million, marking a 24% increase over 2024. Lung Diagnostic Testing contributed $79.2 million in revenue, a 22% increase, from 62,600 tests delivered, which was a 15% increase. Development Services generated $9.3 million in biopharmaceutical services revenue, a 41% increase. The company also enrolled over 1,500 patients in the CLARIFY study, which will gather patient outcomes and clinical information on 4,000 patients who received Nodify Lung® Nodule Risk Assessment testing. Operational efficiencies improved, with the gross margin percentage increasing to 81% from 78% in 2024. The company limited the growth in full-year Operating Expense, excluding Direct costs and expenses, to 10% over 2024, including non-cash share-based compensation expenses, while achieving 24% revenue growth.

Biodesix Inc (NASDAQ:BDSX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 17 items for BDSX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for BDSX spans SCHEDULE 13D/A, 4, 10-Q, 8-K.

Recent high-impact activity:

  • Schuler's Biodesix Stake Hits 22.3% After $1.0M Post-Guidance-Cut Buy
  • 10% Owner Jack Schuler Buys 100,000 Biodesix Shares for $1.0M After Guidance Cut
  • Biodesix Sinks 29% After Q3 Revenue Miss, 2026 Guidance Cut to $101M-$103M
  • Biodesix 10-Q: Q3 Revenue $24.0M, Net Loss Narrows to $8.0M, Cash $28.4M
  • Biodesix Q3 Revenue Misses, Full-Year 2026 Guidance Cut to $101M-$103M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$88.5M
Net Income
-$35.27M
Diluted EPS
-$4.67
Op. Cash Flow
-$23.27M
Free Cash Flow
-$23.53M
Operating Income
-$27.87M
Cash & Equivalents
$18.99M
Total Debt
$50.01M
Debt / Equity
-20.29×
Net Margin
-39.8%
Shares Outstanding
8.25M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076547

Short Interest & Short Volume

2.46 days to cover

FINRA reported short interest of 210,018 shares in BDSX as of the October 30, 2026 settlement, a 0.3% increase from the prior period — about 2.5 days to cover at its recent average daily volume. On November 20, 2026, 53.3% of BDSX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)210,018 shares as of October 30, 2026
Change vs prior period▲ 0.3%
Days to cover2.46 at avg daily volume of 85,505
Daily short volume (FINRA facilities)53.3% of 89,139 shares on November 20, 2026
5-day average short volume59.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for BDSX, detected from its recent SEC filings · based on capital-structure filings through 2026-05-29.

Resale Offering by Selling Stockholder · Origin of Shares

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$7.56
52-week range · as of 2026-11-12 $5.26 – $31.97
Market cap
$83.83M
Volume
205.4K (0.9× avg)
3-mo avg 228.6K
Live data · 2026-11-21 06:17 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BDSX - Latest Insights

BDSX
Nov 12, 2026, 9:29 AM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $7.56 info
Change: -$2.56 (-25%) info
Market Cap: $83.829M info
BDSX
Nov 12, 2026, 9:29 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $7.56 info
Change: -$2.56 (-25%) info
Market Cap: $83.829M info
BDSX
Nov 06, 2026, 3:24 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $7.56 info
Change: -$4.05 (-35%) info
Market Cap: $83.829M info
BDSX
Nov 05, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.00
Real-time Price: $7.56 info
Change: -$8.44 (-53%) info
Market Cap: $83.829M info
BDSX
Nov 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.70
Real-time Price: $7.56 info
Change: -$11.14 (-60%) info
Market Cap: $83.829M info
BDSX
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $18.70
Real-time Price: $7.56 info
Change: -$11.14 (-60%) info
Market Cap: $83.829M info
BDSX
Aug 05, 2026, 4:24 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.78
Real-time Price: $7.56 info
Change: -$15.22 (-67%) info
Market Cap: $83.829M info
BDSX
May 29, 2026, 5:31 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $16.31
Real-time Price: $7.56 info
Change: -$8.75 (-54%) info
Market Cap: $83.829M info
BDSX
May 21, 2026, 4:39 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $15.18
Real-time Price: $7.56 info
Change: -$7.62 (-50%) info
Market Cap: $83.829M info
BDSX
May 04, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $12.12
Real-time Price: $7.56 info
Change: -$4.56 (-38%) info
Market Cap: $83.829M info
BDSX
May 04, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $12.19
Real-time Price: $7.56 info
Change: -$4.63 (-38%) info
Market Cap: $83.829M info
BDSX
Feb 26, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $13.70
Real-time Price: $7.56 info
Change: -$6.14 (-45%) info
Market Cap: $83.829M info
BDSX
Feb 26, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.61
Real-time Price: $7.56 info
Change: -$7.05 (-48%) info
Market Cap: $83.829M info
BDSX
Jan 27, 2026, 2:28 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $10.84
Real-time Price: $7.56 info
Change: -$3.28 (-30%) info
Market Cap: $83.829M info
BDSX
Jan 27, 2026, 9:29 AM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $10.25
Real-time Price: $7.56 info
Change: -$2.69 (-26%) info
Market Cap: $83.829M info
BDSX
Jan 26, 2026, 9:28 AM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $11.78
Real-time Price: $7.56 info
Change: -$4.22 (-36%) info
Market Cap: $83.829M info
BDSX
Jan 12, 2026, 12:04 PM EST
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $9.63
Real-time Price: $7.56 info
Change: -$2.07 (-22%) info
Market Cap: $83.829M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets